ANI Pharmaceuticals, Inc., a diversified biopharmaceutical company, announced that following final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the company has launched prucalopride tablets. ANI’s prucalopride tablets is the generic version of the reference listed drug (RLD) Motegrity.
"We are delighted to build momentum early in 2025 with the approval of the first generic for Motegrity, once again highlighting our superior R&D capabilities. The FDA has granted our prucalopride tablets a competitive generic therapy (CGT) designation, with 180-day exclusivity. ANI continues to hold the second-highest number of CGT approvals in the US generics market,” stated Nikhil Lalwani, president and chief executive officer of ANI.
US annual sales for prucalopride tablets total approximately $168.0 million, based on October 2024 moving annual total (MAT) IQVIA data.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives"" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The company is focused on delivering sustainable growth through its rare disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its generics business, which leverages R&D expertise, operational excellence, and US-based manufacturing; and its established brands business.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!